Industry: Treatment for gastrointestinal disorders
Targut Biotechnologies is developing a new class of drugs to treat gastrointestinal (GI) disorders, such as inflammatory bowel disease, constipation and irritable bowel syndrome, as well as colon cancer prevention. These conditions affect millions of people and have limited treatment options with significant side effects.
Targut's drugs aim to be more effective with fewer side effects compared to current treatments. Existing drugs for colon cancer prevention have side effects like headache, flushing and dyspepsia that can reduce patients' willingness to take them. Also, some patients with heart disease cannot use these drugs due to drug interactions.
Targut's products focus on gut-localized activity, making them a superior option for colon cancer prevention and other GI disorders. They will also be better for patients who experience severe diarrhea from current treatments, improving patient compliance.
Company website: Targut